Radiotherapy's Impact on Survival in Oropharyngeal Cancer with Limited Metastases
Author Information
Author(s): Kharouta Michael, Lorenz F. Jeffrey, Mahase Sean, Shi Hongyun, Goyal Neerav, Yao Min
Primary Institution: Penn State College of Medicine
Hypothesis
Does radiotherapy at the primary tumor site improve survival in patients with oropharyngeal cancer with limited metastases?
Conclusion
Radiotherapy to the primary site can improve overall survival in patients with limited metastatic oropharyngeal cancer, regardless of HPV status.
Supporting Evidence
- Patients receiving radiotherapy showed increased median overall survival from 9.9 to 16.1 months.
- HPV-positive patients had median survival increase from 17.1 to 24.9 months with radiotherapy.
- HPV-negative patients had median survival increase from 8.4 to 12.9 months with radiotherapy.
- 54.6% of patients received radiotherapy to the primary site.
- 69.9% of patients underwent systemic therapy.
Takeaway
This study found that giving radiation therapy to the main tumor can help people with a certain type of throat cancer live longer, even if the cancer has spread a little.
Methodology
Data from the National Cancer Database was analyzed for patients aged 18-90 with limited metastatic oropharyngeal cancer, using statistical models to assess survival outcomes.
Potential Biases
Potential selection bias due to non-randomized treatment assignment.
Limitations
The study is retrospective and observational, lacking data on the number of metastatic lesions and specific radiation protocols.
Participant Demographics
Median age was 61 years; 81% were White, 15.4% Black, and 3.6% other/unknown.
Statistical Information
P-Value
p = 0.0026 for HPV-positive patients receiving RT; p = 0.0047 for HPV-negative patients receiving RT.
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website